3月24日 - ** 制药商Karyopharm Therapeutics KPTI.O股价盘前上涨16%至7.78美元
** 该公司称其selinexor加ruxolitinib组合药物在骨髓纤维化晚期试验中达到了两个主要目标之一，骨髓纤维化是一种罕见的血癌，会导致骨髓瘢痕和脾脏肿大。
** 该公司称，试验达到了缩小脾脏大小的目标，但在症状改善方面与单独使用鲁索利替尼没有明显差异
** 公司还指出了可能的生存获益信号，并表示计划与 FDA 会晤，讨论下一步措施
** 2025 年股价下跌约 27%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.